Literature DB >> 35819472

The Cardioprotective Potential of von Willebrand Disease in Ischemic Heart Disease.

Nawfal Mihyawi1, Muhammad Ajmal2, Ayman R Fath1, Bikash Bhattarai3, Beeletsega Yeneneh4.   

Abstract

von Willebrand factor (vWF) aids coagulation at sites of vessel injury. Elevated vWF levels have been associated with an increased risk of ischemic heart disease (IHD); however, it is unclear whether vWF deficiency, seen in patients with von Willebrand disease (vWD), protects people against IHD. We determined and compared the prevalence and risk of IHD in patients with versus without vWD by using data from the National Inpatient Sample (2009-2014), excluding patients younger than 18 and older than 75 years. The primary outcome was the odds ratio (OR) of IHD in patients with versus without vWD. Secondary outcomes were major medical comorbidities and demographic characteristics in patients with vWD. Of 224,475,443 weighted hospital-discharge samples, we identified 82,809 patients with a vWD diagnosis. The odds of IHD were lower in patients with vWD than in those without (OR=0.54; 95% CI, 0.52-0.56). After multivariable logistic regression analysis and adjustment for age, sex, and typical IHD risk factors (hypertension, smoking, diabetes, hyperlipidemia, chronic kidney disease, obesity, and family history of IHD), the likelihood of IHD remained lower in patients with vWD than in patients without (OR=0.65; 95% CI, 0.63-0.67). Our study shows that vWF deficiency, as seen in patients with vWD, is associated with a decreased prevalence of IHD. Further investigation may confirm these findings.
© 2022 by the Texas Heart® Institute, Houston.

Entities:  

Keywords:  Arteriosclerosis/classification/physiopathology; United States/epidemiology; heart diseases/epidemiology/prevention & control; ischemia/blood; myocardial infarction/pathology; protective factors; retrospective studies; risk factors; von Willebrand diseases/physiopathology; von Willebrand factor/metabolism

Mesh:

Substances:

Year:  2022        PMID: 35819472      PMCID: PMC9427057          DOI: 10.14503/THIJ-20-7402

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  16 in total

Review 1.  Systematic review of discharge coding accuracy.

Authors:  E M Burns; E Rigby; R Mamidanna; A Bottle; P Aylin; P Ziprin; O D Faiz
Journal:  J Public Health (Oxf)       Date:  2011-07-27       Impact factor: 2.341

2.  Resistance to arteriosclerosis in pigs with von Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis.

Authors:  W Fuster; E J Bowie; J C Lewis; D N Fass; C A Owen; A L Brown
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

3.  Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.

Authors:  Salim S Virani; Alvaro Alonso; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Amanda Marma Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Lisa B VanWagner; Connie W Tsao
Journal:  Circulation       Date:  2020-01-29       Impact factor: 29.690

4.  The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.

Authors:  M Cortellaro; C Boschetti; E Cofrancesco; C Zanussi; M Catalano; G de Gaetano; L Gabrielli; B Lombardi; G Specchia; L Tavazzi
Journal:  Arterioscler Thromb       Date:  1992-09

5.  Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand's disease.

Authors:  T R Griggs; R L Reddick; D Sultzer; K M Brinkhous
Journal:  Am J Pathol       Date:  1981-02       Impact factor: 4.307

6.  Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register.

Authors:  C D Seaman; J Yabes; D M Comer; M V Ragni
Journal:  J Thromb Haemost       Date:  2015-10-28       Impact factor: 5.824

7.  Aortic atherosclerosis in pigs with heterozygous von Willebrand disease. Comparison with homozygous von Willebrand and normal pigs.

Authors:  L Badimon; P Steele; J J Badimon; E J Bowie; V Fuster
Journal:  Arteriosclerosis       Date:  1985 Jul-Aug

8.  Arteriosclerosis in normal and von Willebrand pigs: long-term prospective study and aortic transplantation study.

Authors:  V Fuster; D N Fass; M P Kaye; M Josa; A R Zinsmeister; E J Bowie
Journal:  Circ Res       Date:  1982-11       Impact factor: 17.367

9.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  S G Thompson; J Kienast; S D Pyke; F Haverkate; J C van de Loo
Journal:  N Engl J Med       Date:  1995-03-09       Impact factor: 91.245

Review 10.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.